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Death receptor targeting has emerged as one of the promising novel approaches of 
cancer therapy. The activation of one such prototypic death receptor, CD95 
(Fas/APO-1), has remained controversial because CD95 agonistic molecules have 
exhibited either too strong toxicity or too little activity. The natural CD95 ligand 
(CD95L) is a cytokine which needs to trimerize to mediate a cell death signal. Mega-
Fas-Ligand, now referred to as APO010, is a synthetic hexameric CD95 agonist that 
exhibits strong antitumor activity in various tumor models. Here, we studied the 
effects of APO010 in human glioma models in vitro and in vivo. Compared with a 
cross-linked soluble CD95L or a CD95-agonistic antibody, APO010 exhibited 
superior activity in glioma cell lines expressing CD95 and triggered caspase-
dependent cell death. APO010 reduced glioma cell viability in synergy when 
combined with temozolomide (TMZ). The locoregional administration of APO010 
induced glioma cell death in vivo and prolonged the survival of tumor-bearing mice. 
A further exploration of APO010 as a novel anti-glioma agent is warranted. 
 
 




Death ligands of the tumor necrosis factor (TNF) family have been shown to induce 
apoptosis in a variety of human tumor models.1 The prototypic death ligand, CD95L, 
was identified as a natural ligand of receptor molecules previously recognized to be 
activated by cytolytic antibodies referred to as CH11 anti-Fas2 or anti-APO-13 in 
humans or Jo2 in mice.4 Agonistic antibodies to CD955, 6 as well as CD95L7 were 
cytolytic for malignant glioma cells in vitro. In vivo applications were initially not 
further pursued because of hepatotoxicity, despite some preliminary evidence of the 
feasibility at least of a local application.8, 9 CD95 is the principal receptor for CD95L, 
although a soluble decoy receptor, DcR3, has also been identified and may act to 
protect glioma cells from apoptosis.10  
Given the toxicity associated with CD95 agonism, Apo2 ligand/TNF-related 
apoptosis-inducing ligand (Apo2L/TRAIL) became the most promising death ligand 
for an application in the clinic, including malignant glioma.11-13 Apo2L/TRAIL interacts 
with at least five receptors: death receptor (DR)4/TRAIL-R1 and DR5/TRAIL-R2 
transmit an apoptotic signal whereas DcR1/TRAIL-R3 and DcR2/TRAIL-R4 do not. 
Further, osteoprotegerin is a low affinity soluble receptor for Apo2L/TRAIL of 
unknown physiological significance.14 However, even Apo2L/TRAIL was not untoxic 
to normal cells, and it became clear that efficacy and tolerability of Apo2L/TRAIL 
depend on specific modifications of the recombinant cytokine.15 A natural human 
Apo2L/TRAIL referred to as Apo2L.0 containing amino acids 114-281 was presumed 
to be well-tolerated while retaining tumor activity.16 Current clinical trials are testing 
Apo2L in several solid tumors and non-Hodgkin lymphoma (ClinicalTrials.gov 
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identifications NCT00671372, NCT00873756, NCT00400764, NCT00923390, 
NCT00819169 and NCT00508625). 
Both CD95L and Apo2L/TRAIL recruit Fas-associated death domain protein (FADD) 
to their death-promoting receptors and consecutively trigger caspase-mediated cell 
death. In the ongoing search for a potent death ligand with an acceptable safety 
profile, Holler and colleagues (2003) developed the “Mega-Fas-Ligand”, a hexameric 
protein consisting of two CD95L extracellular domain trimers and the collagen 
domain of adiponectin ACRP30.17 This molecule is now known as APO010. Here we 
characterize the cytolytic properties of APO010 on human glioma cells in vitro and in 
vivo and compare its potency to a cross-linked soluble CD95L and an agonistic anti-
CD95 antibody. 
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Materials and Methods 
 
Materials and cell lines  
The human malignant glioma cell lines LN-308, LNT-229 (T for Tübingen for 
clarification) and U87MG were provided by Dr. N. de Tribolet (Centre Hospitalier 
Universitaire Vaudois, Lausanne, Switzerland). The human SV-FHAS astrocytic cell 
line was provided by D. Stanimirovic (Institute of Biological Sciences, National 
Research Council of Canada, Ontario, Ottawa, Canada). The generation of LNT-
229.neo control and LNT-229.MGMT transfectants overexpressing MGMT has been 
described18, as well as the generation of LNT-229 cells overexpressing crm-A.19 To 
stably overexpress CD95, LN-308 cells were transfected with the BCMGS.neo 
expression vector containing the cDNA for CD95 using Metafectene Pro (Biontex, 
Martinsried, Germany). The generation of the expression vector has been described 
.6 The LN-308.CD95 transfectants and the LN-308.neo control cells were selected 
with G418 (500 µg/ml) and LN-308.CD95 cells were further subcloned. Primary 
glioblastoma cells were established from freshly resected tumors, cultured in 
monolayers, and used between passages 4 and 9.20 Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum 
(FCS), 2 mM glutamine and penicillin (100 IU/ml)/streptomycin (100 mg/ml). 
DEVD-amc and zVAD-fmk were obtained from Bachem (Heidelberg, Germany). 
Propidium iodide (PI) was purchased from Sigma (St Louis, MO, USA). 
Temozolomide was obtained from Schering Plough (Kenilworth, NJ). APO010 was 
provided by Topotarget (Copenhagen, Denmark).17 O6-Benzylguanine (O6BG) was a 
gift from Bernd Kaina, Mainz, Germany.21 sCD95L and enhancer were obtained from 
Alexis (Grünberg, Germany). sCD95L consists of the extracellular domain of human 
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CD95L (amino acid 103-281) fused at the N-terminus to a linker peptide (26 amino 
acids) and a FLAG-tag. The cross-linking enhancer increases the biological activity 
by ~50-fold. sCD95L and enhancer were used at a ratio of 1:5. In the following, the 
term sCD95L stands for the combination of sCD95L and the enhancer molecule. An 
agonistic antibody to CD95 (clone CH11) was from Upstate (Lake Placid, NY).2  
 
RNA silencing 
To silence endogenous CD95 expression, U87MG and LNT-229 cells were 
transiently transfected with 50 nM HS_FAS_7 HP validated small interfering RNA 
(siRNA) targeting CD95 from Qiagen (Hilden, Germany; Cat No. SI02654463; sense 
strand 5`-GGAGUACACAGACAAAGCCTT-3`). All Stars non-silencing siRNA from 
Qiagen (Hilden, Germany; Cat No. 1027280) was used as a negative control. Glioma 
cells were seeded in 24 well plates and 24 h later transfected with siRNA using 
Metafectene Pro (Biontex, Martinsried, Germany). The extent of gene silencing was 
verified by analysis of CD95 expression on the cell surface by flow cytometry. 
 
DEVD-amc cleavage assay 
The cells were seeded in 96 well plates, treated as indicated, lysed in 25 mM Tris-
HCl, pH 8.0, 60 mM NaCl, 2.5 mM EDTA, 0.25% Nonidet-P40 for 10 min and DEVD-
amc was added at 12.5 mM. Caspase activity was assessed by fluorescence using a 
Berthold Mithras fluorimeter (Berthold Technologies, Karlsbad, Germany) at 355 nm 
excitation and 475 nm emission wavelengths. 
 
Flow cytometry for CD95 expression 
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Adherent glioma cells were detached using Accutase (PAA, Wien, Austria) and 
blocked with 2% fetal calf serum in phosphate-buffered saline (PBS). The cells were 
incubated for 30 min on ice using the FITC-anti-human CD95 monoclonal antibody 
(clone UB2) or IgG1 isotype control from Beckman Coulter (Fullerton, CA). Flow 
cytometry was performed with a Dako flow cytometer (Dako, Glostrup, Denmark). 
Signal intensity was calculated by dividing median fluorescence obtained with the 
specific antibody by signal intensity obtained with the isotype control antibody 
(specific fluorescence index, SFI). 
 
Detection of apoptosis by annexin V binding 
Apoptotic cell death was analyzed by staining with FITC-labeled annexin V (BD 
Bioscience, Heidelberg, Germany). Glioma cells were treated as indicated, collected, 
washed with PBS, and resuspended in a buffer containing 10 mM HEPES/NaOH (pH 
7.4), 140 mM NaCl, and 2.5 mM CaCl2. Then annexin V-FITC and PI were added. 
After incubation for 30 min, the cells were analyzed by flow cytometry (Dako CyAn 
ADP 7). Cells positive for annexin V binding and negative for PI staining were 
considered as early apoptotic. Cells positive for annexin V binding and positive for PI 
staining were considered as late apoptotic cells.  
 
Growth and viability assay 
The cells were seeded in 96 well plates and allowed to attach for 24 h. Cells were 
treated as indicated and cell density of attached cells was assessed by crystal violet 
staining. Briefly, the cell culture medium was removed and surviving cells were 
stained with 0.5% crystal violet in 20% methanol for 20 min at room temperature. 
The plates were washed extensively under running tap water, air-dried and optical 
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density values were read in an enzyme-linked immunosorbent assay (ELISA) reader 
(Mithras LB 940, Berthold technologies, Bad Wildbad, Germany) at a wavelength of 
550 nm. 
 
Immunoblot analysis  
The general procedure has been described.22 The cells were treated as indicated 
and lysed. 20 µg of protein per lane were separated on 10–12% acrylamide gels 
(Biorad, Munich, Germany). After transfer to a nitrocellulose membrane, the blots 
were pretreated for 1 h with PBS containing 5% skim milk and 0.05% Tween 20 and 
then incubated overnight with the following antibodies: cleaved-caspase 3 (No. 9661) 
from Cell Signaling (Frankfurt, Germany), caspase 8 (ALX-804-429-C100) from 
Alexis (Grünberg, Germany), poly(ADP-ribose) polymerase (PARP; 4C10-5) from BD 
Bioscience and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from 
Chemicon (Billerica, MA). Visualisation of protein bands was accomplished using 
horseradish peroxidase-coupled IgG secondary antibody (Santa Cruz, Santa Cruz, 
CA) and enhanced chemoluminescence (Amersham, Little Chalfont, England). 
 
Animal experiments 
CD1nu/nu mice were purchased from Charles River Laboratories (Sulzfeld, Germany). 
The experiments were performed according to the German animal protection law. 
For the intracranial glioma model, mice aged 6–12 weeks were anesthetized and 
placed in a stereotaxic fixation device (Stoelting, Wood Dale, IL). A burr hole was 
drilled in the skull 2 mm lateral to the bregma. The needle of a Hamilton syringe 
(Darmstadt, Germany) was introduced to a depth of 3 mm. 105 U87MG cells 
resuspended in a volume of 2 µl PBS were injected into the right striatum. 
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Locoregional treatment with APO010 (40 ng in 2 µl PBS on days 7 and 14 after 
tumor implantation) or PBS was performed similarly (6 mice per group). The mice 
employed in our experiments had body weights between 20 g and 30 g. Thus, the 
mice received 0.0013-0.002 mg/kg body weight APO010 i.c.. Systemic treatment 
was performed by i.p. injections of APO010 (0.015 mg per kg body weight 3 times 
per week) or PBS (5 mice per group). These doses were selected based on a 
maximum tolerated dose (MTD) for systemic application according to Verbrugge et 
al.23 and by an MTD determination for i.c. application performed in the context of this 
study. The mice were observed twice daily and killed when developing neurological 
symptoms or at defined time points for histological analysis as indicated. For the 
detection of intratumoral APO010, U87MG tumors were inoculated and the mice 
were treated i.c. or i.p. as described above on day 14 following tumor inoculation. 
Mice were sacrificed 4 h (n = 3) or 24 h (n = 3) respectively following treatment. Mice 
were cardially perfused with cold PBS and brains were snap frozen. The tumors 
were explanted, homogenized and brought into lysis buffer containing a protease 
inhibitor cocktail. Lysates were centrifuged at 6000 turns/minute for 5 min and the 
supernatant extracted for gel electrophoresis and immunoblot using anti-ACRP30 
monoclonal antibody (ALX-804-144, clone ne.na) from Enzo life sciences 
(Farmingdale, NY) which recognizes the collagen domain of adiponectin ACRP30 as 
part of APO010. 
 
Immunohistochemistry 
For histology, 8 mm cryostat sections were stained with H&E. Cleaved caspase-3 
(AF835; R&D Systems, Europe, Belgium) was detected by immunohistochemistry. 
The tissue sections were pretreated with 3% H2O2 in methanol to block endogenous 
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peroxidase and boiled for 10 min in citrate buffer. Endogenous biotin activity was 
blocked with the DAKO biotin blocking kit (DAKOCytomation GmbH, Hamburg, 
Germany). Sections were blocked with 3% skim milk and 10% normal swine serum 
for 30 min each at room temperature. Primary antibodies were added and the tissue 
sections were incubated overnight at 4°C in a humidified chamber. Purified normal 
immunoglobulin G substituted for the specific antibody served as a negative control. 
The sections were washed three times with PBS containing 0.05% Tween 20 
(PBST). Biotinylated goat anti-rabbit secondary antibody (Vector Laboratories, 
Burlingham, CA) was added for 1 h. After three PBST washes, streptavidin 
peroxiase conjugate (Zymed, Berlin, Germany) was added and the tissue sections 
were incubated for 10 min, washed with PBST, and 3-amino-9-ethylcarbazole in 
N,N-dimethylformamide (Zymed) was added as a substrate. After further 10 min of 
incubation, the sections were finally washed with water. Terminal deoxynucleotidyl 
transferase mediated X-dUTP nick end labelling (TUNEL) was performed using the 
TUNEL-AP Kit (Roche, Basel, Switzerland). Neighbouring control sections were 
stained using Mayer’s hematoxylin. All sections were cover-slipped and staining was 
assessed by light microscopy.  
 
Statistics 
Statistical significance was assessed by one-way analysis of variance between 
groups (ANOVA) and Bonferroni post hoc testing or student`s two-tailed t-test as 
indicated (SPSS 17, SPSS, Chicago, Illinois). Synergy of APO010 and TMZ was 
evaluated using the fractional product method. Here, “predicted values” correspond 




APO010 is cytotoxic to human glioma cells 
The human glioma cell lines studied here express different levels of CD95 as 
assessed by flow cytometry using an anti-human CD95 specific antibody (clone 
UB2). The SFI for the present culture conditions were 2.3 for U87MG, 2.1 for LNT-
229 and 1.3 for LN-308. The SFI for SV-FHAS was 1.1. 
The lower level of CD95 expression has been held responsible for the relative 
resistance of LN-308 cells to CD95-mediated apoptosis.6 Accordingly, U87MG and 
LNT-229, but not LN-308, cells were highly sensitive to APO010. At equivalent 
concentrations, APO010 was more effective than sCD95L or CH11 in inducing cell 
death in both cell lines (Fig. 1A-C). Accordingly, APO010 induced DEVD-amc-
cleaving caspase activity in U87MG and LNT-229 cells (Fig. 1D-E), but not in LN-308 
cells (data not shown). Cell death induction involved the cleavage of caspases 8 and 
3 and of PARP, and caspase and PARP processing were blocked by the broad 
spectrum caspase inhibitor, zVAD-fmk (Fig. 1F). The induction of cell death by 
APO010 critically depended on the activation of caspase 8 since LNT-229 cells 
overexpressing crm-A, which selectively blocks caspase 8, were resistant (data not 
shown). 
Cell death induction by APO010 was further characterized by flow cytometry using 
annexin V labelling for the assessment of apoptosis and PI staining for the detection 
of cell death. APO010 was more effective in inducing apoptosis than sCD95L or 
CH11, and the induction of cell death was blocked by zVAD-fmk. Consistent with the 
cell loss depicted in Fig. 1, U87MG and LNT-229 cells were sensitive (Fig. 2A, B) 
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whereas LN-308 cells were resistant (Fig. 2C). Moreover, SV-FHAS astrocytes were 
resistant to APO010 (Fig. 2D). 
Further, we tested primary glioma cell cultures from 9 randomly selected 
glioblastoma patients. These ex vivo propagated cells were treated between 
passage 4 and 9 with either APO010, sCD95L or CH11. Again, APO010 was more 
effective in inducing apoptosis than sCD95L or CH11 as assessed by annexin V / PI 
labelling and flow cytometry (Table). APO010 killed in a concentration-dependent 
manner more than 50% of the cells at a concentration of 1000 ng/ml in seven 
tumors, compared to 3 tumors for SCD95L and none of the tumors for CH11 at 
equivalent concentrations. Only 2 (TU 132 and TU 159) of these 9 tested tumors 
showed relative resistance to APO010-mediated cell death. TU 132 does not 
express CD95 on the cell surface (SFI 1.0) as assessed by flow cytometry and TU 
159 only at a low level (SFI 1.4) (Table). Most of the sensitive tumors show higher 
SFI values for CD95 expression. However, the SFI of the sensitive TU 447 (SFI 1.4) 
corresponded to that of TU 159, indicating regulation of sensitivity at the level of 
down-stream signal transduction, too. 
 
Cytotoxicity of APO010 critically depends on the expression of CD95 
To assess the specificity of the cytotoxic activity of APO010, CD95 expression was 
silenced using siRNA in LNT-229 and U87MG glioma cells. Successful gene 
silencing was verified by flow cytometry 72 h following transfection (Fig. 3A). Time-
course experiments confirmed a stable knock-down of CD95 between 72 and 96 h 
following transfection (data not shown). The knock-down of CD95 led to a significant 
reduction of sensitivity of both cell lines towards APO010-mediated cytotoxicity (Fig. 
3B). To sensitize LN-308 cells towards APO010, these cells were genetically 
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modified to overexpress CD95 and subcloned. The clones LN308.CD95 K2 and K3 
showed stable overexpression of CD95 as assessed by flow cytometry (SFI 7.0 and 
14.4) and gained sensitivity towards APO010 (Fig. 3C). 
 
APO010 synergizes with TMZ in inducing glioma cell death 
The next set of experiments was performed to evaluate additive or synergistic effects 
of APO010 and TMZ, the most commonly used drug for the treatment of 
glioblastoma. According to the fractional product method24, the combination of 
APO010 and TMZ had more than additive, that is, synergistic cytotoxic effects (Fig. 
4A). Resistance to TMZ alone is conferred by the DNA repair enzyme O-6-
methylguanine-DNA methyltransferase (MGMT).18 To assess whether the 
combination of APO010 and TMZ bypassed the protective function of MGMT, we co-
treated MGMT-transfected cells with APO010 and TMZ. No synergy was observed 
under these conditions (Fig. 4B), suggesting that the MGMT-sensitive effects of TMZ 
mediate synergy. Accordingly, when higher, equieffective concentrations for 
monotherapy with TMZ were employed in the MGMT-transfected cells, synergy was 
restored (data not shown). Moreover, preexposure of the MGMT-transfected cells to 
the MGMT inhibitor O6BG and subsequent coexposure to lower concentrations of 
TMZ and APO010 also resulted in synergistic induction of cell loss (Fig. 4C). These 
data corroborated that no specific, MGMT-independent cascade triggered by TMZ 
facilitates APO010-induced apoptosis. Importantly, LN-308 cells, which are resistant 
to death receptor-mediated apoptosis, were sensitized by TMZ to APO010-mediated 
cell death (Fig. 4D). However, since LN-308 cells are also relatively resistant to TMZ-
mediated cell death18, a higher concentration of TMZ compared to LNT-229 cells 
was necessary to achieve this sensitization. Moreover, the synergy of TMZ and 
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APO010 led to enhanced DEVD-amc-cleaving caspase activity in LNT-229 cells (Fig. 
4E).  
 
APO010 induces glioma cell death in vivo and prolongs survival  
Orthotopic human U87MG xenografts were established in nude mice as outlined in 
the Methods section and were confirmed to be associated with intracranial tumor 
growth as assessed by histology. APO010 was administered by stereotactic injection 
on days 7 and 14 after tumor cell implantation. The dose of 40 ng per single injection 
was determined from tolerability studies in preceding applications in non-tumor 
bearing mice. APO010 conferred a significant survival benefit. At 40 days after tumor 
cell implantation, the survival rate was 80% as opposed to 0% in control-treated 
animals (p < 0.01; student`s two tailed t-test). The median survival increased from 37 
to 52 days (Fig. 5A). The subsequent death of the mice in the APO010 treatment 
group was related to neurological symptoms following recurrence of tumor growth as 
assessed macroscopically. 
Systemic treatment was performed by i.p. injections of APO010 with the maximum 
tolerated dose of 0.015 mg/kg body weight three times per week following tumor 
inoculation until the mice had to be sacrificed due to the development of neurological 
symptoms. The survival of the mice in the treatment and PBS control group did not 
differ significantly (p = n.s.; student`s two tailed t-test) (Fig. 5B). 
Histological studies were performed on day 15 after tumor inoculation in i.c.-treated 
mice. H&E staining revealed minimal tumor burden in the APO010 group compared 
to controls (Fig. 5C a and b). Apoptotic tumor cells were detected by TUNEL-staining 
(Fig. 5C c and d) and immunohistochemistry for active caspase 3 (Fig. 5C e and f) 
only in the APO010, but not the control group (Fig. 5C middle and lower panels).  
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The failure of systemic application to limit tumor growth suggested insufficient 
APO010 delivery to the target. Accordingly, to assess intratumoral APO010, tumors 
were implanted and 6 mice per group were treated by a single i.p. or i.c. 
administration of APO010 or PBS as a control. Three mice per group were sacrificed 
4 h and 3 mice 24 h following treatment. Tumor lysates were assessed for APO010 
by immunoblot. APO010 was only detected in the tumors from mice injected i.c. with 
APO010, but not in the APO010 i.p. or the PBS control groups (Fig. 5D). At 24 h 
(Fig. 5D, lower panel), note a weak band in lane 3 and only background signal in 




















This article reports on a further development in the field of death receptor targeting 
for malignant glioma. We find that APO010, a novel hexameric CD95 agonist17, is 
superior to either soluble CD95L or the agonistic CD95 antibody CH11 in killing 
CD95-expressing U87MG and LNT-229 glioma cells (Fig. 1 and 2). Superior activity 
of APO010 over other CD95 agonists has previously been observed in leukemia and 
SKOV-3 ovarian cancer cells.25, 26 The induction of cell death in glioma cells was 
specific in that it was receptor-mediated. In LN-308 cells, which express very little 
CD95, a significant induction of cell death was observed only for the highest dosis of 
APO010 (Fig. 1C and 2C) and LNT-229 cells overexpressing crm-A were resistant to 
APO010 (data not shown). Moreover, in contrast to human Apo2L/TRAIL, which 
failed to kill freshly isolated glioma cells27, activity of APO010 was also observed in 
various primary glioma cell cultures (Table). The CD95 gene silencing in LNT-229 or 
U87MG cells abrogated, and the overexpression of CD95 in LN-308 cells conferred 
sensitivity of these cells (Fig. 3). Therefore, the cell surface expression of CD95 is a 
prerequisite for the cytotoxic action of APO010 and the expression level of CD95 a 
gross indicator for the sensitivity. However, the susceptibility of the cell lines is likely 
modulated additionally by down-stream intra-cellular targets, e.g. caspases and 
inhibitor of apoptosis proteins (IAP). Compared with LNT-229 cells, U87MG cells 
express similar levels of X-linked IAP28, but much higher levels of caspase 929, 
suggesting that these cells amplify the mitochondrial cell death pathway more 
efficiently. Such observations explain that cell lines expressing similar amounts of 
CD95 may show different sensitivities. 
 
 16
Additive or synergistic effects of death ligands and chemotherapy have been studied 
extensively in various cancer models, including malignant gliomas.7, 13, 30 APO010 
exhibited enhanced activity when combined with platinum in ovarian cancer cells25 or 
imatinib in gastrointestinal stromal tumors.31 In contrast, no synergistic effect of 
APO010 was demonstrated in vivo when combined with irradiation.23 In view of a 
possible clinical application, we combined APO010 with TMZ, the current standard of 
care chemotherapy for glioblastoma.32 There was compelling evidence for synergy 
as assessed by the fractional product method and this synergy required the classical 
MGMT-sensitive cell death pathway triggered by TMZ (Fig. 4). Sensitization of 
glioma cells towards Apo2L/TRAIL-mediated apoptosis by lomustine, another 
alkylating chemotherapeutic agent, involved the mitochondrial pathway and 
enhanced cytochrome c release.30 Another report demonstrated an upregulation of 
CD95 following treatment of U87MG cells with the O6-methylating agent N-methyl-N-
nitro-N-nitrosoguanide by immunoblot in membrane extracts.33 In this study, we did 
not observe an upregulation of CD95 on the cell surface by flow cytometry under 
conditions of synergistic killing in LN-308 cells (data not shown).  
 
Local injection of APO010 conferred a significant survival benefit to glioma-bearing 
mice in the absence of relevant toxicity (Fig. 5). APO010 was only active in vivo 
when administered locally, but not when given intraperitoneally. Assessment of 
tumors ex vivo revealed APO010 only in the i.c.-treated group, but not following i.p. 
injection (Fig. 5D). This suggests that upon systemic treatment with the maximum 
tolerated dose, too little, if any, APO010 reaches the tumor. In general, the toxicity of 
the human APO010 in mice in vivo has been favourable compared with the mouse 
Jo2 antibody. When applied in BALB/c mice, 100 µg of Jo2 killed most of the mice 
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and 10 µg killed half of the mice when given i.p..4 In contrast, APO010 has been 
administered systemically23 or intraperitoneally25 or intralesionally in the brain in this 
study and controlled tumor growth in the absence of unacceptable toxicity as 
assessed by clinical observation of the mice and immunohistochemistry. The MTD 
for APO010 was 0.015 mg/kg body weight for systemic treatment23 and 40 ng per 
single injection for local intracerebral treatment as determined here. Kamei et al. 
used the anti-CD95 antibody, clone CH11, in a mouse model of melanoma and 
injected 5 µg of the antibody directly in the tumors grown s.c. in nude mice. This was 
tolerated, but did not affect tumor growth.34 The injection of up to 10 µg CH11 into 
s.c. growing tumors derived from SNB19 or SNB79 glioblastoma cell lines was 
tolerated, too, but did not alter tumor growth either.35 In the same study, mice were 
also injected up to 10 µg CH11 intravenously. A MTD was not formally determined in 
either study. 
The MTD of APO010 (40 ng) and CH11 (10 µg) for local treatment are difficult to 
compare since APO010 was used in an orthotopic model and injected i.c. while CH-
11 was only tested in s.c. inoculated tumors. No study available has directly 
compared APO010 directly with an anti-CD95 antibody or a soluble Fas ligand in 
vivo. However, in the present study, APO010 exhibited anti-glioma activity when 
injected directly in the tumor while CH11 failed to exhibit activity when injected s.c. in 
mouse models of melanoma or glioblastoma as indicated above. 
APO010 is now being explored in a phase I dose-escalation study in up to 35 
patients with untreatable advanced or refractory solid tumours in order to establish 
the safety and tolerability and maximum tolerated dose in man (ClinicalTrials.gov 
identification NCT00437736). In addition, pharmacokinetics, immunogenicity and 
preliminary signs of anti-cancer activity are evaluated.  
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Table. APO010 induces apoptotic cell death in ex vivo human glioma cell 
cultures. Cell cultures were generated from freshly resected tumor specimens from 
nd 
H11 for 20 h in triplicates. Cell 
xperiments with 
EVD-cleaving caspase 
f statistical significance for a superior effect of APO010 over 
10 
 
nine randomly selected glioblastoma patients. Cells were treated between passages 
4 and 9 as indicated for 20 h. Apoptosis was assessed by Annexin V/PI labelling a
flow cytometry. Data are expressed as mean % of annexin V positive cells ± SEM (n 
= 1 to 3; n.d. = not defined). CD95 expression was assessed by flow cytometry and 
SFI values are indicated. 
 
Fig. 1. APO010 induces DEVD-amc-cleaving caspase activity and cell death in 
human glioma cell lines. A-C. U87MG, LNT-229 or LN-308 cells were exposed to 
increasing concentrations of APO010, sCD95L or C
density was assessed by crystal violet staining. Data are expressed as mean and 
standard deviation (n=3), one representative out of 3 independent e
similar results is shown. D-E. U87MG or LNT-229 cells were treated as in A and B in 
triplicates and assessed at 3 (U87MG) or 6 h (LNT-229) for D
activity. Data are expressed in relation to untreated controls as mean and standard 
deviation (n=3), one representative out of 3 independent experiments with similar 
results is shown. Level o
sCD95L and CH11 was assessed in A-E by one-way ANOVA and Bonferroni post-
hoc testing (* p < 0.05; ** p < 0.01; *** p < 0.001; ++ describes p < 0.01 for APO0
and sCD95L vs. CH11). F. LNT-229 cells were treated as indicated for 20 h. Cellular 
lysates were examined for cleavage of caspases 8 and 3, for PARP and GAPDH by 
immunoblot.  
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Fig. 2. Caspase-dependent induction of annexin V/PI labelling by APO010. The 
cells were treated with CD95 agonists as indicated and characterized by annexin 
V/PI labelling 6 h (U87MG) or 20 h (LNT-229) later. Quantitative data for U87MG, 
percentage of annexin V positive cells ± SEM from 3 
95si) or scrambled control siRNA (scr). A. Seventy-
ssed as mean percentages of annexin V-positive cells ± 
ing concentrations of APO010 for 20 h in triplicates in a 96 well 
ts with similar results is shown. Level of statistical 
LNT-229, LN-308 and SV-FHAS cells are provided in A-D. Coexposure to zVAD-fmk 
(50 μM) was included to assess the caspase dependency of cell death induction. 
Data are expressed as mean 
independent experiments. Level of statistical significance was assessed by one-way 
ANOVA and Bonferroni post-hoc testing (** p < 0.01). 
 
Fig. 3. Targeted alterations in CD95 expression at the cell surface result in 
altered sensitivity towards APO010. U87MG or LNT-229 cells were transfected 
with siRNA targeting CD95 (CD
two h after transfection the cells were assessed for the expression of CD95 by flow 
cytometry. B. Seventy-two h after transfection the cells were treated with APO010 
(200 ng/ml) and characterized by annexin V/PI labelling 6 h (U87MG) or 20 h (LNT-
229) later. Data are expre
SEM from 3 independent experiments. C. LN-308 cells were stably transfected to 
overexpress CD95. Subclones LN-308.CD95 K2 or K3 and LN308.neo controls were 
exposed to increas
format. Cell density was assessed by crystal violet staining. Data are expressed in 
relation to untreated controls as mean and SEM (n=3). One of 3 representative 
independent experimen
significance was assessed by one-way ANOVA and Bonferroni post-hoc testing (* p 
< 0.05; ** p < 0.01).  
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ic induction of cell death by APO010 and TMZ. LNT-229 cells 
ere treated with TMZ for 96 h followed by APO010 for another 20 h. The graphs 
M) (C) and LN-308 cells (TMZ 600 μM) (D). (E) LNT-229 
ells were pretreated with TMZ (90 μM) as indicated above followed by addition of 
 and B with a single injection. After perfusion of the mice with PBS, the 
Fig. 4. Synergist
w
show the results of treatment with either agent alone, the predicted effect assuming 
independent (additive) effects, and the truly observed effect. The bars express the 
percentage of living cells as assessed by flow cytometry after annexin V and PI 
staining. The data are expressed as mean and SEM from 3 independent 
experiments. We studied LNT-229.neo control cells (TMZ 90 μM) (A), MGMT-
transfected cells (TMZ 90 μM) (B), MGMT-transfected cells additionally treated with 
O6BG (50 µM; TMZ 90 μ
c
APO010 and assessed at 6 h for DEVD-amc-cleaving caspase activity. Data are 
expressed relative to untreated controls as mean and standard deviation (n=3). One 
representative out of 3 independent experiments with similar results is shown.  
 
Fig. 5. Locoregional APO010 administration induces glioma cell death in vivo 
and prolongs the survival of tumor-bearing mice. A. The mice were treated i.c. 
with PBS or APO010 (40 ng) on days 7 and 14 after the intracranial implantation of 
105 U87MG cells and monitored for survival. B. The mice were treated with PBS or 
APO010 (0.015 mg/kg body weight) i.p. three times per week and monitored for 
survival. C. The animals were treated as in A and tumors were removed on day 15 
after tumor inoculation and stained with H&E (a,b) or for apoptotic cell death by 
TUNEL (c,d) or immunohistochemistry for activated caspase 3 (e,f). Size bar in the 
lower right panel: 40 µm. Analysis of statistical significance was performed by 
student`s two-tailed t-test (** p < 0.01; n.s. not significant). D. Mice were treated as 
described in A
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mors were removed 4 h (upper panel) or 24 h (lower panel) after treatment. Pooled tu
tumor lysates were subjected to immunoblot and APO010 was assessed using an 
anti-ACRP30 antibody (clone ne.na). Purified APO010 served as a positive control. 
 






